Stay updated on Dapagliflozin-Induced Liver Injury Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin-Induced Liver Injury Clinical Trial page.

Latest updates to the Dapagliflozin-Induced Liver Injury Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe updated page shows a revised layout and styling, but core study content (purpose, eligibility criteria, primary outcomes, enrollment, dates, and locations) appears unchanged. No significant data changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedCore page now includes a government funding lapse notice and a new v3.2.0 release, replacing v3.1.0; this affects perceived reliability and versioning of the page.SummaryDifference5%

- Check46 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. This is a metadata revision with no substantive content changes.SummaryDifference0.1%

- Check60 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed, with no substantive content changes.SummaryDifference0.3%

- Check67 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.3%

- Check75 days agoChange DetectedThe web page has updated its facility name and location to specify Washington D.C., District of Columbia, United States, while removing several previous location-related terms and resources.SummaryDifference3%

Stay in the know with updates to Dapagliflozin-Induced Liver Injury Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin-Induced Liver Injury Clinical Trial page.